Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation
NCT ID: NCT04651166
Last Updated: 2023-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
48 participants
INTERVENTIONAL
2022-02-15
2023-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
NCT06820177
Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery
NCT02302456
Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section
NCT04427618
Tranexamic Acid in Preventing Postpartum Hemorrhage in High Risk Pregnancies During Elective Cesarean Section
NCT03351686
Role of Prophylactic Tranexamic Acid in Reducing Blood Loss During Elective Caesarean Section for Placenta Praevia Major
NCT04350645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
100mL saline or lactated ringer without tranexamic acid added given intravenously over 10 minutes at start of procedure
Placebo
100mL saline or lactated ringers
Active Comparator
1g tranexamic acid mixed in 100mL saline or lactated ringer given intravenously over 10 minutes at start of procedure
Tranexamic acid
1g tranexamic acid mixed in 100mL saline or lactated ringer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic acid
1g tranexamic acid mixed in 100mL saline or lactated ringer
Placebo
100mL saline or lactated ringers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intrauterine pregnancy at 16 to 24 weeks gestation
* Participants must be willing and capable of giving informed consent and able to understand and sign written consents in English.
Exclusion Criteria
14 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Society of Family Planning
OTHER
University of Hawaii
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marit Pearlman Shapiro
Complex Family Planning Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marit Pearlman Shapiro
Role: PRINCIPAL_INVESTIGATOR
University of Hawaii
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queens Medical Center
Honolulu, Hawaii, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA-2020-050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.